CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 64 enrolled
Drug / intervention
PDM608 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05950906
NCT05950906Phase 1Completed
CompareCT.gov

A Two-Part Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of PDM608 in Healthy Adult Subjects

Calibr, a division of Scripps Research·interventional·Posted Jul 18, 2023·Updated Nov 18, 2025

In Brief

A Phase 1 clinical trial evaluating PDM608 and Placebo for Parkinson Disease. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
CollaboratorsMichael J. Fox Foundation for Parkinson's Research, Alzheimer's Drug Discovery Foundation

Timeline

Phase 1CompletedFinished
202420252026
First PostedJul 18, 2023
Enrollment StartJun 27, 2023
Primary CompletionMar 17, 2024
Study CompletionApr 19, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.0 years ago

Interventions

PDM608drug

PDM608 subcutaneous at single or multiple dose(s) assigned by cohort

Placebodrug

Placebo subcutaneous at single or multiple dose(s) to match PDM608 administration.